Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc has a collaboration agreement with Microsoft to scale digital, data and AI capabilities across the business and accelerate delivery of its global win as one strategy. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.…
PG Raises Sales Outlook as Thorne Acquisition Adds Growth Potential
Haleon (LON: HLN) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 24,535 employees.
The shares were at 345.30 GBp on 20 November 2026, down 8.4% over 52 weeks. Its 52-week range is 310.50 GBp to 416.10 GBp: the price is 17.0% below the high and 11.2% above the low.
At a market capitalisation of 30.27B GBP, it trades at 19.2 times trailing earnings and 15.5 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 26.1, a discount of 27% for HLN. It pays a dividend yielding 2.13% (it pays out 39% of its earnings), against a median of 1.86% among the dividend payers in that peer group.
Haleon reports return on equity of 10.1%, an operating margin of 23.5% and revenue up 2.2% year over year.
Its debt exceeds its cash by 7.43B GBP, a debt-to-equity ratio of 0.52. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 18 analysts cover the stock, with an average rating of Buy; their mean price target of 377.56 GBp is 9.3% above the current price. The next earnings report is expected on 25 February 2027.